Stock Research: Chunghwa Chemical Synthesis & Biotech

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Chunghwa Chemical Synthesis & Biotech

TSEC:1762 TW0001762003
8
  • Value
    41
  • Growth
    10
  • Safety
    Safety
    60
  • Combined
    18
  • Sentiment
    14
  • 360° View
    360° View
    8
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company manufacturing and distributing biotechnology and chemical synthetic products. The company's main businesses include biotechnology products (e.g., pravastatin, rapamycin, tacrolimus) and non-biotechnology products (e.g., methocarbamol, guaifenesin), applied in drugs for various treatments including cough, diabetes, cardiovascular diseases, high blood pressure, and immune system diseases. It operates in domestic and overseas markets, including Asia, the Americas, and Europe. In the last fiscal year, the company had a market cap of $73 million, profits of $12 million, and revenue of $41 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 8 (better than 8% compared with alternatives), overall professional sentiment and financial characteristics for the stock Chunghwa Chemical Synthesis & Biotech are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Chunghwa Chemical Synthesis & Biotech. Only the consolidated Value Rank has an attractive rank of 60, which means that the share price of Chunghwa Chemical Synthesis & Biotech is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 60% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 10, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 41, meaning the company has a riskier financing structure than 59% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 86% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 14. ...read more

more
Index
FTSE Taiwan
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
60 54 80 73
Growth
10 14 47 100
Safety
Safety
41 38 61 72
Sentiment
14 70 41 100
360° View
360° View
8 38 64 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
18 20 20 97
Opinions Change
50 50 50 50
Pro Holdings
n/a 52 30 98
Market Pulse
53 91 100 100
Sentiment
14 70 41 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
60 54 80 73
Growth
10 14 47 100
Safety Safety
41 38 61 72
Combined
18 13 79 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
8 26 97 95
Price vs. Earnings (P/E)
58 51 57 63
Price vs. Book (P/B)
97 83 65 63
Dividend Yield
30 64 67 65
Value
60 54 80 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
79 22 67 98
Profit Growth
4 28 15 26
Capital Growth
42 54 81 96
Stock Returns
4 16 39 91
Growth
10 14 47 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
35 33 47 94
Refinancing
72 63 57 27
Liquidity
14 31 61 61
Safety Safety
41 38 61 72

Similar Stocks

Discover high‑ranked alternatives to Chunghwa Chemical Synthesis & Biotech and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Hon Hai Precision Industry

TSEC:2317
Country: Taiwan
Industry: Electr. Manufacturing Services
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.